.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Poster
P 063

The β-catenin/CREB-binding protein (CBP) inhibitor PRI-724 acts as a broad-spectrum antiviral in in vitro and ex vivo model systems

Appointment

Date: 04/03/2025

Time: 13:30 – 13:30

Talk time: 0 Min.

Discussion time: 0 Min.

Location / Stream:

Building VMP 6 (I)

Session

Antiviral therapy and resistance

Topic

Antiviral therapy and resistance

Authors

Maximilian A. Kelch (Frankfurt a.M. / DE), Alicia Hiemisch (Jena / DE), Jeremy Sousa (Frankfurt a.M. / DE), Professor Denisa Bojkova (Frankfurt a.M. / DE), Professor Rainer König (Jena / DE), Dr. Tuna Toptan (Munich / DE)